Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children - FDA
This article was originally published in PharmAsia News
Takeda's direct-to-consumer TV ad for the insomnia drug Rozerem (ramelteon) fails to disclose the drug's indication, does not include information related to side effects and suggests through "back to school"-themed images and statements that the drug is indicated in children, FDA says in a warning letter issued to the company March 5 and posted online March 8
You may also be interested in...
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.
Independent review panel will be established to handle complaints about pharmaceutical advertising.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).